We have observed correlations between RIPK2 activation, AMPK loss and YAP proliferation in inflammatory bowel disease patients [12] to suggest a link between key elements involved in ImmunoMET oncogenesis. This evidence concerns the gene RIPK2 and inflammatory bowel disease.